INS and Hypoglycemia: However, in population‐based data only approximately 30% of individuals with T1D are near target HbA1c (<7.5%/59 mmol/mol) and at least 30% have poor control (HbA1c ≥ 9.0%/75 mmol/mol).4 A key barrier to optimizing glycaemia is hypoglycaemia; in the DCCT, rates of severe hypoglycaemia were 3‐fold higher in those randomized to intensive therapy and with HbA1c at or below target.5 Another long‐term issue is insulin‐induced weight gain, which may be accompanied by escalating insulin dose requirements, increased LDL cholesterol and/or raised blood pressure (BP).6, 7, 8